Zimmer Biomet Announces Chief Financial Officer Transition
Rhea-AI Summary
Zimmer Biomet (NYSE: ZBH) announced that Suketu Upadhyay, Chief Financial Officer and Executive Vice President, Finance, Operations and Supply Chain, will depart effective April 28, 2026, to pursue a new professional opportunity. The company named Paul Stellato, Controller and Chief Accounting Officer, as interim CFO while it conducts an internal and external search for a permanent successor.
Stellato joined Zimmer Biomet in May 2022, has more than 20 years of finance and investor-relations experience, and previously held senior finance roles at Xylem and ITT; he is a CPA with degrees from Villanova and NYU Stern.
Positive
- Interim CFO Paul Stellato named to provide continuity during the transition
- Stellato brings 20+ years of finance and investor-relations experience
- Stellato joined Zimmer Biomet in May 2022 and led corporate FP&A efforts
Negative
- CFO Suketu Upadhyay departing effective April 28, 2026, creating leadership turnover
- Company will run an internal and external search for a permanent CFO
News Market Reaction – ZBH
In the Apr 28 session, ZBH declined 10.57%, reflecting a significant negative market reaction. Argus tracked a trough of -7.6% from its starting point during tracking. Our momentum scanner triggered 110 alerts that day, indicating very high trading interest and price volatility. Trading volume was very high at 3.9x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Earnings call scheduling | Neutral | +0.0% | Announcement of timing and access details for Q1 2026 earnings call. |
| Apr 07 | Leadership appointment | Positive | +0.4% | Appointment of new Chief Science, Technology and Medical Affairs Officer. |
| Feb 25 | Conference showcase | Positive | -0.0% | Plan to present new data and innovations at AAOS 2026 meeting. |
| Feb 23 | Dividend declaration | Positive | +0.7% | Announcement of $0.24 quarterly cash dividend for Q1 2026. |
| Feb 10 | Earnings results | Positive | +1.9% | Strong Q4/FY 2025 sales, EPS, cash flow and new share repurchase plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ZBH news, especially earnings and capital return updates, has mostly aligned with modest positive price reactions, with only one slight divergence on a product/clinical data showcase.
Over the past few months, ZBH has reported several operational and financial milestones. Q4 2025 results showed net sales of $2.244B and full-year sales of $8.232B, alongside strong cash generation and a new $1.5B share repurchase authorization. The company also declared a $0.24 quarterly dividend for Q1 2026 and announced new leadership in science and medical affairs. Conference and webcast announcements around February–April 2026 have generally seen small but positive price follow-through.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Suketu Upadhyay to Depart; Paul Stellato Named Interim CFO
WARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced Suketu Upadhyay, Chief Financial Officer and Executive Vice President, Finance, Operations and Supply Chain, will depart the company effective April 28 for a new professional opportunity.
The company has named Paul Stellato, currently Controller and Chief Accounting Officer, as interim Chief Financial Officer, while the company conducts an internal and external search to identify a permanent successor.
"We are deeply grateful for Suky's leadership and contributions to Zimmer Biomet over the past seven years," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "We are confident Paul is the right leader to provide continuity and steady direction during this transition, as we continue to execute our strategy and deliver on our commitments."
A seasoned operator, Stellato brings more than 20 years of broad financial and Investor Relations experience to the role. He currently serves as Controller, Chief Accounting Officer and head of Corporate FP&A at Zimmer Biomet. Since joining the company in May 2022, Stellato has advanced Zimmer Biomet's strategy and transformation through disciplined capital allocation, including recent acquisitions and its share repurchase program.
Previously, Stellato was a member of Xylem Inc.'s finance leadership team, where he held multiple roles during his tenure, including Vice President of Finance for Global Business Services; Vice President, Controller and Chief Accounting Officer; and Vice President of Financial Planning and Analysis. Stellato also spent eight years at ITT Corporation, where he held various roles of increasing responsibility in the finance organization. He spent his early career in public accounting with both Andersen and Ernst & Young. Stellato holds a Bachelor of Science in Accountancy from Villanova University and a Master of Business Administration from the Stern School of Business at
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the
Contacts: | |
Media | Investors |
Troy Kirkpatrick | David DeMartino |
614-284-1926 | 646-531-6115 |
Kirsten Fallon | Zach Weiner |
781-779-5561 | 908-591-6955 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-chief-financial-officer-transition-302754861.html
SOURCE Zimmer Biomet Holdings, Inc.